An immunopotentiator, ophiopogonin D, encapsulated in a nanoemulsion as a robust adjuvant to improve vaccine efficacy

Sahdev, 2014, Biomaterials for nanoparticle vaccine delivery systems, Pharm. Res., 31, 2563, 10.1007/s11095-014-1419-y Ulmer, 2006, Vaccine manufacturing: challenges and solutions, Nat. Biotechnol., 24, 1377, 10.1038/nbt1261 Lee, 2015, Recent advances of vaccine adjuvants for infectious diseases, Immune Network, 15, 51, 10.4110/in.2015.15.2.51 Vartak, 2016, Recent advances in subunit vaccine carriers, Vaccines, 4, 10.3390/vaccines4020012 Baylor, 2002, Aluminum salts in vaccines–US perspective, Vaccine, 20, S18, 10.1016/S0264-410X(02)00166-4 Gerdts, 2015, Adjuvants for veterinary vaccines–types and modes of action, Berl. Munch. Tierarztl. Wochenschr., 128, 456 Sun, 2009, Advances in saponin-based adjuvants, Vaccine, 27, 1787, 10.1016/j.vaccine.2009.01.091 Brunner, 2017, QS-21 adjuvant: laboratory-scale purification method and formulation into liposomes, Methods Mol. Biol., 1494, 73, 10.1007/978-1-4939-6445-1_5 Zhu, 2016, QS-21: a potent vaccine adjuvant, Nat. Prod. Chem. Res., 3 Kennedy, 2008, The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers, Vaccine, 26, 4420, 10.1016/j.vaccine.2008.05.090 Ragupathi, 2011, Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer, Exp. Rev. Vaccines, 10, 463, 10.1586/erv.11.18 Vandepapeliere, 2008, Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers, Vaccine, 26, 1375, 10.1016/j.vaccine.2007.12.038 Fernandez-Tejada, 2017, Semisynthesis of analogues of the saponin immunoadjuvant QS-21, Methods Mol. Biol., 1494, 45, 10.1007/978-1-4939-6445-1_4 Waite, 2001, Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21, Vaccine, 19, 3957, 10.1016/S0264-410X(01)00142-6 Zhang, 2018, Soybean oil containing ginseng saponins as adjuvants promotes production of cytokines and enhances immune responses to foot-and-mouth disease vaccine, Microbiol. Immunol., 62, 187, 10.1111/1348-0421.12567 Rivera, 2003, Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants, Vaccine, 21, 1149, 10.1016/S0264-410X(02)00518-2 Song, 2009, Adjuvant activities of saponins from traditional Chinese medicinal herbs, Vaccine, 27, 4883, 10.1016/j.vaccine.2009.06.033 Jiang, 2014, A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats, BMC Complement. Altern. Med., 14, 350, 10.1186/1472-6882-14-350 Huang, 2015, Ophiopogonin D: a new herbal agent against osteoporosis, Bone, 74, 18, 10.1016/j.bone.2015.01.002 Oda, 2000, Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants, Biol. Chem., 381, 67, 10.1515/BC.2000.009 Schijns, 2006, “Immunopotentiators in Modern Vaccines” (IMV-II) held in Malaga, Spain, May 18–20, 2005, Vaccine, 24, 5391, 10.1016/j.vaccine.2006.03.053 Schijns, 2008, New views on immunopotentiators in modern vaccines, Exp. Rev. Vaccines, 7, 877, 10.1586/14760584.7.7.877 Song, 2016, Enhanced efficacy and anti-biofilm activity of novel nanoemulsions against skin burn wound multi-drug resistant MRSA infections, Nanomed.: Nanotechnol., Biol., Med., 12, 1543, 10.1016/j.nano.2016.01.015 Sun, 2015, Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine, Int. J. Nanomed., 10, 7275, 10.2147/IJN.S91529 Sun, 2012, Development and characterization of a novel nanoemulsion drug-delivery system for potential application in oral delivery of protein drugs, Int. J. Nanomed., 7, 5529, 10.2147/IJN.S36071 Lindell, 2011, A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease, PloS One, 6, 10.1371/journal.pone.0021823 Francica, 2017, Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs, Blood Adv., 1, 2329, 10.1182/bloodadvances.2017011411 Kotta, 2014, Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation, Int. J. Pharm., 462, 129, 10.1016/j.ijpharm.2013.12.038 Yang, 2018, Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection, RSC Adv., 8, 10425, 10.1039/C8RA00154E Zuo, 2013, Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection, PloS One, 8, 10.1371/journal.pone.0081212 Selvarajan, 2011, Peritoneal macrophages are distinct from monocytes and adherent macrophages, Atherosclerosis, 219, 475, 10.1016/j.atherosclerosis.2011.09.014 Margina, 2015, Natural products-friends or foes?, Toxicol. Lett., 236, 154, 10.1016/j.toxlet.2015.05.009 Pourgholaminejad, 2016, The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells, Cytokine, 85, 51, 10.1016/j.cyto.2016.06.003 Zhang, 2014, Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis, Pharm. Res., 31, 1015, 10.1007/s11095-013-1224-z Woof, 2005, Immunology. Tipping the scales toward more effective antibodies, Science, 310, 1442, 10.1126/science.1122009 Ranieri, 2014, CTL ELISPOT assay, Methods Mol. Biol., 1186, 75, 10.1007/978-1-4939-1158-5_6 Murtaugh, 2002, Inflammatory cytokines and antigen presenting cell activation, Vet. Immunol. Immunopathol., 87, 109, 10.1016/S0165-2427(02)00042-9 Jiang, 2017, Qualitative and quantitative analysis of multiple components for quality control of Deng-Zhan-Sheng-Mai capsules by ultra high performance liquid chromatography tandem mass spectrometry method coupled with chemometrics, J. Sep. Sci., 40, 612, 10.1002/jssc.201600744 Zhang, 2015, Ophiopogonin D attenuates doxorubicin-induced autophagic cell death by relieving mitochondrial damage in vitro and in vivo, J. Pharmacol. Exp. Ther., 352, 166, 10.1124/jpet.114.219261 Fleck, 2006, Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice, Vaccine, 24, 7129, 10.1016/j.vaccine.2006.06.059 Bomford, 1992, Adjuvanticity and ISCOM formation by structurally diverse saponins, Vaccine, 10, 572, 10.1016/0264-410X(92)90435-M Xie, 2008, Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses, Int. Immunopharmacol., 8, 1143, 10.1016/j.intimp.2008.04.006 Palatnik de Sousa, 2004, Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins, Vaccine, 22, 2470, 10.1016/j.vaccine.2004.01.072 Xie, 2008, Contribution of the glycidic moieties to the haemolytic and adjuvant activity of platycodigenin-type saponins from the root of Platycodon grandiflorum, Vaccine, 26, 3452, 10.1016/j.vaccine.2008.04.023 Oliveira-Freitas, 2006, Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis, Vaccine, 24, 3909, 10.1016/j.vaccine.2006.02.034 Garcon, 2007, GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives, Exp. Rev. Vaccines, 6, 723, 10.1586/14760584.6.5.723 Zhang, 2015, Immunopotentiator-loaded polymeric microparticles as robust adjuvant to improve vaccine efficacy, Pharm. Res., 32, 2837, 10.1007/s11095-015-1666-6 Smith, 2013, Applications of nanotechnology for immunology (vol 13, pg 592, 2013), Nat. Rev. Immunol., 13, 10.1038/nri3517 Akagi, 2012, Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine, Adv. Polym. Sci., 247, 31, 10.1007/12_2011_150 Mann, 2009, Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection, Vaccine, 27, 3643, 10.1016/j.vaccine.2009.03.040 De Gregorio, 2014, From empiricism to rational design: a personal perspective of the evolution of vaccine development, Nat. Rev. Immunol., 14, 505, 10.1038/nri3694 Guy, 2005, New adjuvants for parenteral and mucosal vaccines, Therapie, 60, 235, 10.2515/therapie:2005030 Riese, 2013, Vaccine adjuvants: key tools for innovative vaccine design, Curr. Top. Med. Chem., 13, 2562, 10.2174/15680266113136660183 Sjolander, 1998, ISCOMs: an adjuvant with multiple functions, J. Leukocyte Biol., 64, 713, 10.1002/jlb.64.6.713